Disclosed is use of an RPN2 gene expression inhibitor as a cancer cell proliferation inhibitor. If required, the cancer cell proliferation inhibitor may further contain an agent having an anti-cancer activity. If required, the cancer cell proliferation inhibitor may be administered together with atelocollagen. Also disclosed is an anti-cancer agent comprising the cancer cell proliferation inhibitor.
